Catalent (NYSE: CTLT) reported Q2 EPS of $0.45, $0.08 better than the analyst estimate of $0.37. Revenue for the quarter came in at $623 million versus the consensus estimate of $607.91 million.

• Q2'19 revenue of $623.0 million increased 3% as-reported, or 5% in constant currency, from the prior-year period.
• Q2'19 YTD revenue of $1,174.8 million increased 2% as-reported, or 4% in constant currency, from the prior-year period.
• Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery and Clinical Supply Services segments; Juniper acquisition continues to out-perform internal expectations.
• FY'19 financial guidance reaffirmed.

“We're very pleased with our financial performance during the second quarter, which included strong growth within our Biologics and Specialty Drug Delivery segment,” said John Chiminski, Chair, President and Chief Executive Officer of Catalent, Inc. “In addition, the Juniper Pharmaceuticals acquisition, which closed during the first quarter and provides both additional spray-drying capability and a European early-stage formulation and development center of excellence, continues to perform ahead of our expectations and is creating value for our customers and shareholders.”

GUIDANCE:

Catalent sees FY2019 revenue of $2.5-2.59 billion, versus the consensus of $2.51 billion.

For earnings history and earnings-related data on Catalent (CTLT) click here.